For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
6
views
100
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,532
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      SGLT2 inhibitors: an evidence-based update on cardiovascular implications

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references100

          • Record: found
          • Abstract: not found
          • Article: not found

          2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

          Theresa A McDonagh, Marco Metra, Marianna Adamo … (2021)
          Article 0 comments Cited 2975 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

            Bernard Zinman, Christoph Wanner, John M. Lachin … (2015)
            The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
            Article 0 comments Cited 2497 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

              John J.V. McMurray, Scott D. Solomon, Silvio E Inzucchi … (2020)
              In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.
              Article 0 comments Cited 1997 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Gaetano Santulli: (View ORCID Profile)
                Journal
                Title: Expert Opinion on Investigational Drugs
                Abbreviated Title: Expert Opinion on Investigational Drugs
                Publisher: Informa UK Limited
                ISSN (Print): 1354-3784
                ISSN (Electronic): 1744-7658
                Publication date Created: September 02 2023
                Publication date (Electronic): October 02 2023
                Publication date (Print): September 02 2023
                Volume: 32
                Issue: 9
                Pages: 839-847
                Affiliations
                [1 ]International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, “Federico II” University, Naples, Italy
                [2 ]Department of Medicine (Division of Cardiology), Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, New York City, NY, USA
                [3 ]Department of Medicine, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Aging Research, Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York City, NY, USA
                [4 ]Department of Medicine and Health Sciences “Vincenzo Tiberio, University of Molise, Campobasso, Italy
                [5 ]Department of Molecular Pharmacology, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, New York City, NY, USA
                Article
                DOI: 10.1080/13543784.2023.2263354
                PubMed ID: 37740906
                SO-VID: 608b8553-4b2e-405d-8879-8bb5c08cf4e8
                Copyright © © 2023
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,532

                See all similar

                Cited by3

                See all cited by

                Most referenced authors2,412

                See all reference authors